Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- PE ratio
- —
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 90,500
- Avg volume
- 251,470
- Day's range
- $0.02 – $0.02
- Shares out
- —
- Stochastic %K
- 44%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- —
Company profile
Rhelion Life Sciences Corp. engages in the research and development of psychedelic drug in Netherlands, Canada, and the United States. Its products also include PEX010, a natural psilocybin drug candidate. It also engages in the production, growth, and sale of functional mushrooms and mushroom home grow kits to the recreational market in North America and Europe, as well as selection, distribution, and export of truf...
Show more
Rhelion Life Sciences Corp. engages in the research and development of psychedelic drug in Netherlands, Canada, and the United States. Its products also include PEX010, a natural psilocybin drug candidate. It also engages in the production, growth, and sale of functional mushrooms and mushroom home grow kits to the recreational market in North America and Europe, as well as selection, distribution, and export of truffles. The company was formerly known as Red Light Holland Corp. and changed its name to Rhelion Life Sciences Corp. in August 2026. Rhelion Life Sciences Corp. is based in Toronto, Canada.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 647 204 7129
- Website
- https://www.rhelion.com
- Address
- 1 Adelaide Street East, Suite 801, Toronto, Canada
Latest news
No headlines yet.
